Production (Stage)
Harmony Biosciences Holdings, Inc.
HRMY
$35.42
-$0.18-0.51%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 184.73M | 201.27M | 186.04M | 172.81M | 154.62M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 184.73M | 201.27M | 186.04M | 172.81M | 154.62M |
| Cost of Revenue | 31.99M | 54.41M | 42.78M | 32.14M | 27.48M |
| Gross Profit | 152.74M | 146.86M | 143.26M | 140.67M | 127.13M |
| SG&A Expenses | 61.95M | 56.47M | 56.16M | 55.73M | 52.91M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 128.49M | 145.54M | 124.33M | 151.46M | 102.58M |
| Operating Income | 56.25M | 55.73M | 61.71M | 21.36M | 52.03M |
| Income Before Tax | 57.18M | 56.16M | 62.17M | 21.69M | 51.79M |
| Income Tax Expenses | 11.62M | 6.68M | 16.08M | 10.10M | 13.45M |
| Earnings from Continuing Operations | 45.56M | 49.48M | 46.09M | 11.59M | 38.33M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 45.56M | 49.48M | 46.09M | 11.59M | 38.33M |
| EBIT | 56.25M | 55.73M | 61.71M | 21.36M | 52.03M |
| EBITDA | 62.21M | 61.70M | 67.68M | 27.41M | 58.16M |
| EPS Basic | 0.80 | 0.87 | 0.81 | 0.20 | 0.68 |
| Normalized Basic EPS | 0.62 | 0.61 | 0.68 | 0.24 | 0.57 |
| EPS Diluted | 0.78 | 0.85 | 0.79 | 0.20 | 0.67 |
| Normalized Diluted EPS | 0.61 | 0.60 | 0.67 | 0.24 | 0.56 |
| Average Basic Shares Outstanding | 57.31M | 57.10M | 56.87M | 56.80M | 56.77M |
| Average Diluted Shares Outstanding | 58.52M | 58.22M | 58.10M | 57.54M | 57.60M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |